JZXB
Research type
Research Study
Full title
FRAmework-01: A Two-Part Phase 3 Study of LY4170156 versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and LY4170156 plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer
IRAS ID
1013382
Contact name
Emily Coss
Contact email
Sponsor organisation
Eli Lilly and Company
Clinicaltrials.gov Identifier
Research summary
This study, called FRAmework-01, is a Phase 3 clinical trial testing a new cancer drug called LY4170156. It focuses on women with advanced ovarian cancer that has either stopped responding to standard platinum-based chemotherapy (platinum-resistant) or has returned after treatment (platinum-sensitive).
The study has two parts:
Part A includes patients with platinum-resistant ovarian cancer. They will receive either LY4170156 alone or a standard treatment chosen by their doctor, which may include chemotherapy or another drug called mirvetuximab (MIRV).
Part B includes patients with platinum-sensitive ovarian cancer. They will receive either LY4170156 combined with another drug called bevacizumab, or a standard chemotherapy combination with bevacizumab.
LY4170156 is a new type of targeted therapy called an antibody-drug conjugate (ADC). It aims to attack cancer cells that have a protein called folate receptor alpha (FRα), which is often found in ovarian cancer cells. Unlike some existing treatments, LY4170156 may work even in patients with lower levels of this protein.
The main goal of the study is to see if LY4170156 can delay the progression of cancer better than current treatments. Researchers will also look at overall survival, side effects, and how the treatment affects patients’ quality of life.
About 1,080 patients will take part in this global study. The results will help determine if LY4170156 should become a new treatment option for women with advanced ovarian cancer.REC name
London - South East Research Ethics Committee
REC reference
26/LO/0046
Date of REC Opinion
4 Feb 2026
REC opinion
Further Information Favourable Opinion